In a study investigating the potential of targeting ACYP1 in combination with levatinib, a first-line therapy for advanced HCC, it was found that this dual targeting significantly increased HCC sensitivity to levatinib and slowed tumor progression [100]. This evidence concerns the gene ACYP1 and neoplasm.